Dr. Kris Discusses Methotrexate in ALL

Mark G. Kris, MD
Published: Tuesday, Jun 14, 2011

Mark G. Kris, MD from Memorial Sloan-Kettering Cancer Center discusses Methotrexate in Acute Lymphocytic Leukemia (ALL).

Dr. Kris says that by using a regimen that included high dose methotrexate with leucovorin rescue, the cure rate was improved to over 80%. Using this, which Dr. Kris says has now become a standard of care, more than 80% of children with Acute Lymphocytic Leukemia are cured and that the boost in the cure rate was only by changing how methotrexate is given.
Mark G. Kris, MD from Memorial Sloan-Kettering Cancer Center discusses Methotrexate in Acute Lymphocytic Leukemia (ALL).

Dr. Kris says that by using a regimen that included high dose methotrexate with leucovorin rescue, the cure rate was improved to over 80%. Using this, which Dr. Kris says has now become a standard of care, more than 80% of children with Acute Lymphocytic Leukemia are cured and that the boost in the cure rate was only by changing how methotrexate is given.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x